This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2013
  • /
  • 09
  • /
  • EU approves Giotrif for NSCLC patients with EGFR m...
Drug news

EU approves Giotrif for NSCLC patients with EGFR mutations

Read time: 1 mins
Last updated:27th Sep 2013
Published:27th Sep 2013
Source: Pharmawand

The European Commission has granted marketing authorisation for Giotrif (afatinib), from Boehringer, for the treatment of patients with metastatic Non-Small Cell Lung Cancer whose tumours express specific types of epidermal growth factor receptor (EGFR) gene mutations.

Approval was given on the basis of data from the Phase III LUX-Lung 3 trial which showed that patients on afatinib as a first-line treatment lived for 11.1 months without their tumour growing again versus 6.9 months for those treated with pemetrexed/cisplatin. A further analysis showed that NSCLC patients with tumours containing the EGFR mutations Del19 or L858R experienced median progression-free survival of 13.6 months with the drug, versus a PFS of 6.9 months with the comparator.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.